Rezolute , Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development of its lead drug candidate, ersodetug, for the treatment of congenital ...

Wedbush boosted their FY2029 earnings estimates for shares of Rezolute in a report released on Thursday, February 13th.

Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Rezolute in a research report issued on ...

Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...

However, when several insiders are buying, like in the case of Rezolute, Inc. (NASDAQ:RZLT), it sends a favourable message to the company's shareholders. While we would never suggest that ...

Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...

The primary focus of Rezolute's pipeline is ersodetug, which is currently undergoing Phase 3 trials for both CHI and tumor-induced HI. The sunRIZE trial for CHI has been actively enrolling ...

Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/105.rO--PLCW.js ...

The primary focus of Rezolute's pipeline is ersodetug, which is currently undergoing Phase 3 trials for both CHI and tumor-induced HI. The sunRIZE trial for CHI has been actively enrolling patients ...

REDWOOD CITY, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company ...

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation Open-label arm (infant ...